stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Revenue growth
ADMA Biologics Inc's revenue growth over the twelve months to 30 September 2026 was 6.26%, down 13.4 percentage points from fiscal 2025 (19.6%). Over the past ten years it has ranged from −25.4% (fiscal 2018) to 113.5% (fiscal 2017); the current reading is higher than 18% of that period. That is in line with the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 19.6% | (45.52) |
| FY2024 | 65.2% | (2.44) |
| FY2023 | 67.6% | (22.77) |
| FY2022 | 90.4% | (1.36) |
| FY2021 | 91.7% | 47.87 |
| FY2020 | 43.9% | (28.94) |
| FY2019 | 72.8% | 98.16 |
| FY2018 | −25.4% | (138.86) |
| FY2017 | 113.5% | 64.96 |
| FY2016 | 48.5% | 27.19 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 5.12% | 3.14 |
| Jun 2026 | 1.98% | 2.25 |
| Mar 2026 | −0.27% | (18.66) |
| Dec 2025 | 18.4% | 6.39 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| VCEL Vericel Corporation compare | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc compare | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| ADMA ADMA Biologics Inc | 6.26% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement